Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Chinese authorities approve anti-HBV drug for marketing

Jan. 11, 1999

Sigma ligands synthesized at Jouveinal, evaluated and claimed for GI disorders

Jan. 8, 1999

Oxis announces initial results of phase IIa clinical trial in ulcerative colitis

Jan. 8, 1999

SciClone continues to receive and seek approvals for Zadaxin

Jan. 5, 1999

Antiulcer effects and mechanism of action of AU-006 explored

Jan. 4, 1999

NO donor effective in canine ischemic liver injury model

Dec. 30, 1998

FR-167653 proves effective against ischemic liver damage

Dec. 30, 1998

Effects of TAK-044 in canine model of liver ischemia-reperfusion injury

Dec. 29, 1998

Pharmacokinetics of YJA-20379-8 not affected by water deprivation in rats

Dec. 28, 1998

Previously reported anti-H. pylori cephem characterized in greater detail at recent congress

Dec. 22, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...